20 studies found for:    "Ovarian carcinosarcoma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Neoplasm;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Ruxolitinib Phosphate;   Procedure: Therapeutic Conventional Surgery
2 Recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Drug: WEE1 Inhibitor AZD1775
3 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers
Conditions: Cervical Adenosarcoma;   Cervical Adenosquamous Carcinoma;   Cervical Carcinosarcoma;   Cervical Squamous Cell Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Mucinous Adenocarcinoma;   Endometrial Squamous Cell Carcinoma;   Endometrial Transitional Cell Carcinoma;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Epithelial Tumor;   Malignant Peritoneal Neoplasm;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Skin Melanoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma;   Uterine Corpus Carcinosarcoma
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study
4 Active, not recruiting Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Cognitive Side Effects of Cancer Therapy;   Malignant Ovarian Epithelial Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Choriocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Dysgerminoma;   Ovarian Embryonal Carcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Germ Cell Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Polyembryoma;   Ovarian Sarcoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Teratoma;   Ovarian Yolk Sac Tumor;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
5 Active, not recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions: Biological: Bevacizumab;   Drug: Temsirolimus
6 Active, not recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Tumor;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Veliparib
7 Active, not recruiting Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Ovarian Carcinosarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Sarcoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Sarcoma;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ifosfamide;   Other: Quality-of-Life Assessment
8 Active, not recruiting Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Conditions: Advanced Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Ovarian Carcinosarcoma
Intervention: Drug: Avastin
9 Completed
Has Results
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Conditions: Fallopian Tube Cancer;   Female Reproductive Cancer;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Uterine Sarcoma;   Stage III Ovarian Epithelial Cancer;   Stage III Uterine Sarcoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: ziv-aflibercept
10 Completed Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
Conditions: Fallopian Tube Carcinoma;   Infectious Disorder;   Neutropenia;   Ovarian Carcinosarcoma;   Primary Peritoneal Carcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Procedure: Adjuvant Therapy;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pegfilgrastim
11 Completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: docetaxel;   Biological: bevacizumab
12 Terminated
Has Results
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
Condition: Cancer
Interventions: Drug: cyproheptadine hydrochloride;   Other: placebo
13 Completed Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
Condition: Cancer
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
14 Unknown  Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel
15 Completed BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Conditions: Breast Cancer;   Endometrial Cancer;   Head and Neck Cancer;   Melanoma (Skin);   Ovarian Cancer;   Sarcoma
Interventions: Drug: BI 2536;   Other: high performance liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
16 Completed Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: quality-of-life assessment
17 Completed Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
18 Completed Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Sarcoma
Interventions: Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride
19 Completed Immunotoxin Therapy in Treating Patients With Advanced Cancer
Conditions: Cervical Cancer;   Fallopian Tube Cancer;   Head and Neck Cancer;   Lung Cancer;   Malignant Mesothelioma;   Ovarian Cancer;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Biological: SS1(dsFv)-PE38 immunotoxin
20 Completed Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Conditions: Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Sarcoma
Interventions: Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride

Indicates status has not been verified in more than two years